Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $135.54.
A number of research firms have commented on BNTX. JPMorgan Chase & Co. upgraded shares of BioNTech from an “underweight” rating to a “neutral” rating and increased their price objective for the company from $91.00 to $125.00 in a research note on Monday, September 16th. HSBC boosted their target price on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, September 19th. HC Wainwright lifted their price target on BioNTech from $113.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Finally, Hsbc Global Res upgraded shares of BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd.
Check Out Our Latest Report on BNTX
Institutional Inflows and Outflows
BioNTech Stock Down 1.4 %
Shares of NASDAQ:BNTX opened at $111.48 on Friday. The stock has a 50-day simple moving average of $109.72 and a 200-day simple moving average of $95.77. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. The stock has a market capitalization of $26.51 billion, a P/E ratio of -49.33 and a beta of 0.24.
BioNTech (NASDAQ:BNTX – Get Free Report) last issued its quarterly earnings data on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The firm had revenue of $128.70 million during the quarter, compared to analyst estimates of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The firm’s revenue was down 23.3% compared to the same quarter last year. During the same period last year, the business earned ($0.86) EPS. Equities analysts forecast that BioNTech will post -2.93 earnings per share for the current year.
About BioNTech
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
See Also
- Five stocks we like better than BioNTech
- Why Invest in High-Yield Dividend Stocks?
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- How to Invest in the FAANG Stocks
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- Why is the Ex-Dividend Date Significant to Investors?
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.